🟢 BEAM surges 4.7% following recent FDA clearance for BEAM-304 gene-editing trial

Beam Therapeutics (BEAM) is trading 4.7% up today at $35.53. This follows recent positive developments for its gene-editing pipeline:

• The U.S. FDA recently cleared the Investigational New Drug (IND) application for BEAM-304 for Phenylketonuria (PKU) in June 2026, a significant catalyst for investor optimism.
• Analysts maintain a broadly bullish outlook on the company's gene-editing programs, highlighting substantial upside to consensus price targets.
• The stock is outperforming a mixed broader market today, reflecting company-specific strength.